EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report

Kevin Lu, Sandip P Patel, Tali Azenkot

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.05.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Kevin Lu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of California, San Diego, La Jolla, CA. Electronic address: K9lu@health.ucsd.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The optimal treatment of uncommon, compound EGFR-mutated NSCLC is poorly defined due to heterogeneous responses to targeted therapies. PATIENTS AND METHODS: We retrospectively reviewed patient characteristics and treatment outcomes from cohorts of advanced EGFR-mutated NSCLC patients at UC San Diego Health and the American Association of Cancer Research GENIE database. RESULTS: In our institutional cohort, L858R-mutated patients were significantly more likely to have a de novo compound mutation than those with exon19del (24/159 [15%] vs. 4/228 [2%], P 13 months, and those with G719X alone had a median TTF < 7 months. CONCLUSION: Our findings demonstrate that compound EGFR mutations comprise distinct subgroups with unique clinical characteristics and different responses to targeted therapy. For example, osimertinib may be a viable treatment for patients with compound G719X/L861Q mutations. Further characterization of these heterogeneous subgroups is warranted for identifying optimal treatment strategies as novel targeted agents emerge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationHumansErbB ReceptorsRetrospective StudiesFemaleMaleIndolesPyrimidinesAgedAniline CompoundsAcrylamidesMiddle AgedAged, 80 and overProtein Kinase InhibitorsTreatment Outcome

Stichwörter der Autor:innen

Atypical EGFRNSCLCPACCPrecision oncologyUncommon EGFR

Substanzen

ErbB ReceptorsEGFR protein, humanIndolesPyrimidinesosimertinibAniline CompoundsAcrylamidesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, University of California, San Diego, La Jolla, CA. Electronic address: K9lu@health.ucsd.edu.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA.

Zitieren

APA

Lu, K., Patel, S. P., & Azenkot, T. (2026). Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.05.005

Vancouver

Lu K, Patel SP, Azenkot T. Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.05.005

BibTeX
@article{Lu2026,
  author = {Lu, Kevin and Patel, Sandip P and Azenkot, Tali},
  title = {Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.05.005}
}
Kostenlos starten →